Frequency of common karyotypic abnormalities among WHO and FAB subgroups
| Classification . | No. . | Karyotype, no. (%) . | |||||
|---|---|---|---|---|---|---|---|
| Normal . | del(5q) . | −7/del(7q) . | +8 . | −20/del(20q) . | Complex . | ||
| All FAB | 1949 | 942 (48.3) | 295 (15.1) | 209 (10.7) | 162 (8.3) | 86 (4.4) | 282 (14.5) |
| RA | 573 | 267 (46.6) | 139 (24.3) | 30 (5.2) | 37 (6.5) | 31 (5.4) | 47 (8.2) |
| RARS | 252 | 147 (58.3) | 23 (9.1) | 24 (9.5) | 14 (5.6) | 9 (3.6) | 20 (7.9) |
| RAEB | 415 | 179 (43.1) | 71 (17.1) | 60 (23.8) | 39 (9.4) | 21 (5.1) | 98 (23.6) |
| RAEB-t | 305 | 132 (43.3) | 38 (12.5) | 50 (16.4) | 30 (9.8) | 16 (5.2) | 68 (22.3) |
| CMML | 272 | 170 (62.5) | 4 (1.5) | 23 (8.5) | 18 (6.6) | 2 (<1) | 12 (4.4) |
| MDS-AL | 132 | 47 (30.9) | 20 (15.2) | 22 (16.7) | 25 (18.9) | 7 (5.3) | 37 (28.0) |
| All WHO | 595 | 285 (47.8) | 110 (18.5) | 53 (8.9) | 40 (6.7) | 22 (3.7) | 71 (11.9) |
| 5q− syndrome | 61 | 0 (0.0) | 61 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| RA | 56 | 38 (67.9) | 3 (6.5) | 5 (10.9) | 1 (2.2) | 1 (2.2) | 6 (13.0) |
| RARS | 26 | 23 (88.5) | 0 (0.0) | 0 (0.0) | 1 (3.8) | 0 (0.0) | 0 (0.0) |
| RCMD | 164 | 88 (53.7) | 11 (6.7) | 20 (12.2) | 12 (7.3) | 8 (4.8) | 18 (11.0) |
| RSCMD | 77 | 34 (44.2) | 8 (10.4) | 8 (10.4) | 8 (10.4) | 3 (3.9) | 12 (15.6) |
| RAEB-I | 90 | 42 (45.7) | 16 (17.8) | 10 (11.1) | 5 (5.6) | 4 (4.4) | 15 (16.7) |
| RAEB-II | 121 | 60 (49.6) | 11 (9.1) | 8 (6.6) | 13 (10.7) | 5 (4.1) | 19 (15.7) |
| Classification . | No. . | Karyotype, no. (%) . | |||||
|---|---|---|---|---|---|---|---|
| Normal . | del(5q) . | −7/del(7q) . | +8 . | −20/del(20q) . | Complex . | ||
| All FAB | 1949 | 942 (48.3) | 295 (15.1) | 209 (10.7) | 162 (8.3) | 86 (4.4) | 282 (14.5) |
| RA | 573 | 267 (46.6) | 139 (24.3) | 30 (5.2) | 37 (6.5) | 31 (5.4) | 47 (8.2) |
| RARS | 252 | 147 (58.3) | 23 (9.1) | 24 (9.5) | 14 (5.6) | 9 (3.6) | 20 (7.9) |
| RAEB | 415 | 179 (43.1) | 71 (17.1) | 60 (23.8) | 39 (9.4) | 21 (5.1) | 98 (23.6) |
| RAEB-t | 305 | 132 (43.3) | 38 (12.5) | 50 (16.4) | 30 (9.8) | 16 (5.2) | 68 (22.3) |
| CMML | 272 | 170 (62.5) | 4 (1.5) | 23 (8.5) | 18 (6.6) | 2 (<1) | 12 (4.4) |
| MDS-AL | 132 | 47 (30.9) | 20 (15.2) | 22 (16.7) | 25 (18.9) | 7 (5.3) | 37 (28.0) |
| All WHO | 595 | 285 (47.8) | 110 (18.5) | 53 (8.9) | 40 (6.7) | 22 (3.7) | 71 (11.9) |
| 5q− syndrome | 61 | 0 (0.0) | 61 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| RA | 56 | 38 (67.9) | 3 (6.5) | 5 (10.9) | 1 (2.2) | 1 (2.2) | 6 (13.0) |
| RARS | 26 | 23 (88.5) | 0 (0.0) | 0 (0.0) | 1 (3.8) | 0 (0.0) | 0 (0.0) |
| RCMD | 164 | 88 (53.7) | 11 (6.7) | 20 (12.2) | 12 (7.3) | 8 (4.8) | 18 (11.0) |
| RSCMD | 77 | 34 (44.2) | 8 (10.4) | 8 (10.4) | 8 (10.4) | 3 (3.9) | 12 (15.6) |
| RAEB-I | 90 | 42 (45.7) | 16 (17.8) | 10 (11.1) | 5 (5.6) | 4 (4.4) | 15 (16.7) |
| RAEB-II | 121 | 60 (49.6) | 11 (9.1) | 8 (6.6) | 13 (10.7) | 5 (4.1) | 19 (15.7) |